Overview

Webcast ImageWebcast
Audentes Therapeutics Inc at Chardan Inaugural Gene Therapy Conference (Replay)
10/10/17 at 10:45 a.m. ET
Audentes Therapeutics Inc at Chardan Inaugural Gene Therapy Conference
Tuesday, October 10, 2017 10:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$25.00
Change (%) Stock is Down 3.08 (10.94%)
Volume328,179
Data as of 10/16/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $25.00 with a 52 week high of $33.43 and a 52 week low of $13.13.
Recent NewsMore >>
10/03/17
Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT132 to Treat X-Linked Myotubular Myopathy
09/27/17
Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy
09/21/17
Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.